比克特格拉维尔对持续的低水平病毒病和免疫反应的影响. 贝莱尔研究:一个试点前性观察性研究
Vasilis Petrakis1, Petros Rafailidis1, Nikoleta Babaka1
1Department of Infectious Diseases, 2nd University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece.
International journal of STD & AIDS
|December 6, 2025
概括
比克特格拉维尔/emtricitabine/tenofovir alafenamide (BIC/TAF/FTC) 改善了艾滋病毒感染者 (PWHIV) 经历持续低水平病毒性病 (LLV) 的免疫反应和病毒抑制. 这种组合疗法降低了LLV,并提高了经过治疗的PWHIV患者的CD4+T细胞计数.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 有限的现实世界的数据存在于管理持久的低水平病毒性病 (LLV) 在艾滋病毒感染者 (PWHIV).
- 了解LLV对抗药性和病毒学失败 (VF) 的影响对于有效的HIV治疗至关重要.
- 持续的LLV在临床管理和长期治疗结果方面带来了挑战.
研究的目的:
- 评估比克特格拉维尔 (BIC) 在改善持久LLV的治疗经验丰富的PWHIV病毒学结果方面的疗效.
- 评估切换到BIC/TAF/FTC对病毒抑制和免疫标记物的影响.
- 调查BIC/TAF/FTC在管理LLV和预防病毒学失败中的作用.
主要方法:
- 一项观察性前性研究包括治疗经验丰富的PWHIV与持续的LLV,他们转向BIC/TAF/FTC.
- 收集了人口统计和临床数据,以及CD4+T细胞计数,CD4/CD8比率和HIV-RNA水平.
- 在BIC/TAF/FTC开始后的24个月内,使用SPSS版本19.0.0分析了数据.
主要成果:
- BIC/TAF/FTC显著增加了CD4+T细胞的平均数量 (从485.85增加到619.45,p<0.001).
- 病毒抑制在2个月后达到了58.1%,在12个月后达到了90.3%,维持了24个月.
- 观察到CD4/CD8比率显著增加 (0.51至0.69,p < 0.001).
结论:
- BIC/TAF/FTC证明了在持续的LLV的情况下改善PWHIV免疫反应的潜力.
- 组合治疗可能会降低患有持续LLV的PWHIV患者的比例.
- 需要进行更大规模的研究,以充分阐明比克特格拉维尔在这种患者群体中的益处.
相关概念视频
Retroviruses
12.2K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.2K
Bioavailability Study Design: Single Versus Multiple Dose Studies
388
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
388
Bioavailability Study Design: Healthy Subjects Versus Patients
252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
Bioequivalence studies: Biowaivers
433
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
433
Viral Hepatitis I: Introduction
28
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
28


